High-dose Tamoxifen Modulates Drug Resistance to Doxorubicin, Dacarbazine and Ifosfamide in Metastatic Uterine Leiomyosarcoma

Anticancer Research

Volumn 23, Issue 6 D, 2003, Pages 5133-5137

  Yeh, Kun Huei ^a,b,c   Lu, Yen Shen ^b,c   Hsiao, Chi Huang ^a,b   Cheng, Ann Lii ^b,c  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Dacarbazine; Doxorubicin; Ifosfamide; Leiomyosarcoma; Tamoxifen

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYTOCHROME P450; DACARBAZINE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; GLYCOPROTEIN P; IFOSFAMIDE; MESNA; MULTIDRUG RESISTANCE PROTEIN; TAMOXIFEN;

ABDOMINAL HYSTERECTOMY; ADULT; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CASE REPORT; DRUG INFUSION; DRUG MEGADOSE; FEMALE; HUMAN; LEIOMYOSARCOMA; LUNG METASTASIS; MULTIDRUG RESISTANCE; NEPHROTOXICITY; POSTOPERATIVE CARE; PRIORITY JOURNAL; SPINE METASTASIS; TREATMENT OUTCOME; UTERUS CANCER; UTERUS SARCOMA; UTERUS TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; IFOSFAMIDE; LEIOMYOSARCOMA; MIDDLE AGED; NEOPLASM METASTASIS; TAMOXIFEN; UTERINE NEOPLASMS;

EID: 0842343492     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B and Trump DL: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11: 1276-1285, 1993.
2. Pearl ML, Inagami M, McCauley DL, Valea FA, Chalas E and Fischer M: Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas. Int J Gynecol Cancer 12: 745-748, 2002.
3. Cheng AL, Yeh KH, Luo YJ, Chuang SE and Chen DS: Synergistic effect of doxorubicin and tamoxifen in the treatment of hepatocellular carcinoma. Proc Am Assoc Cancer Res 36: 347 (abstract 2065), 1995.
4. Cocconi G, Bella M, Calabresi F, Tonato M, Canaletti R and Boni C: Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 327: 516-523, 1992.
5. McClay EF, McClay MET, Albright KD, Jones JA, Christen RD, Alcaraz J and Howell SB: Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. Cancer 72: 1914-1918, 1993.
6. Stuart NSA, Philip P, Harris AL, Tonkin K, Houlbrook S, Kirk J, Lien EA and Carmichael J: High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines. Br J Cancer 66: 833-839, 1992.
7. Del Prete SA, Maurer LH, O'Donnell J, Forcier RJ and LeMarbre P: Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 68: 1403-1405, 1984.
8. McClay EF, Mastrangelo MJ, Berd D and Bellet RE: Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 50: 553-556, 1992.
9. Lama G, Angelucci C, Bruzzese N, Iacopino F, Nori SL, D'Atri S, Turriziani M, Bonmassar E and Sica G: Sensitivity of human melanoma cells to oestrogens, tamoxifen and quercetin: is there any relationship with type I and II oestrogen binding site expression? Melanoma Res 8: 313-322, 1988
10. O'Brain CA, Liskamp RM, Solomon DH and Weinstein IB: Triphenylethylenes: a new class of protein kinase C inhibitors. J Natl Cancer Inst 76: 1243-1246, 1986.
11. Berman E, Adams M, Duigou-Osterndorf R, Godfrey L, Clarkson B and Andreeff M: Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood 77: 818-825, 1991.
12. Beulz-Riche D, Robert J, Riche C and Ratanasavanh D: Effects of paclitaxel, cyclophosphamide, ifosfamide, tamoxifen and cyclosporine on the metabolism of methoxymorpholinodoxorubicin in human liver microsomes. Cancer Chemother Pharmacol 49: 274-280, 2002.
13. Dive C, Evans CA and Whetton AD: Induction of apoptosis - new targets for cancer chemotherapy. Semin Cancer Biol 3: 417-427, 1992.
14. Cheng AL, Chuang SE, Fine RL, Yeh KH, Liao CM, Lay JD and Chen DS: Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochemical Pharmacol 55: 523-531, 1998.
15. Mandlekar S, Yu R, Tan TH and Kong AN: Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res 60: 5995-6000, 2000.
16. Blackwell K L, Haroon ZA, Shan S, Saito W, Broadwater G and Greenberg CS: Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clin Cancer Res 6: 4359-4364, 2000.
17. McNamara DA, Harmey J, Wang JH, Kay E, Walsh TN and Bouchier-Hayes DJ: Tamoxifen inhibits endothelial cell proliferation and attenuates VEGF-mediated angiogenesis and migration in vivo. Eur J Surg Oncol 27: 714-718, 2001.
18. Chu PG, Arber DA, Weiss LM and Chang KL: Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. Modern Pathology 14: 465-471, 2001.
19. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan VC and Fine RL: High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: Phase I trial in combination with vinblastine. J Natl Cancer Inst 84: 1811-1816, 1992.
20. Yeh KH and Cheng AL: High-dose tamoxifen reverse drug resistance to cisplatin and etoposide in a patient with advanced large cell carcinoma of lung. Anticancer Res 17: 1341-1343, 1997.
21. Yang CH, Cheng AL, Yeh KH, Yu CJ, Lin JF and Yang PC: High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable non-small cell lung carcinoma. Cancer 86: 415-420, 1999.
22. Cheng AL, Chen YC, Yeh KH, Chuang SE, Chen BR and Chen DS: Chronic oral VP-16 and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. Cancer 77: 872-877, 1996.
23. Cheng AL, Yeh KH, Fine RL, Chuang SE, Yang CH, Wang LH and Chen DS: Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma. Hepatogastroenterology 45: 1955-1960, 1998.
24. Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HKB, Verma S, Armitage GR, Zee B and Bennett K: Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol 14: 2083-2090, 1996.
25. Lattanzi SC, Tosteson T, Chertoff J, Maurer LH, O'Donnell J, LeMarbre PJ, Mott L, DelPrete SA, Forcier RJ and Ernstoff MS: Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res 5: 365-369, 1995.
26. Cocconi G, Passalacqua R, Foladore S, Carlini P, Acito L, Maiello E, Marchi M, Gebbia V, Di Sarra, S, Beretta M and Bacchi M: Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen, or vindesine plus tamoxifen: a prospective randomized study. Melanoma Res 13: 73-79, 2003.
27. Flaherty LE, Liu PY, Mitchell MS, Fletcher WS, Walker MJ, Goodwin JW, Stephens RL and Sondak VK: The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma: a phase II trial of the Southwest Oncology Group (SWOG-8921). Am J Clin Oncol 19: 108-113, 1996.
28. Gerson SL: Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20: 2388-2399, 2002.
29. Chiarenza A, Lazarovici P, Lempereur L, Cantarella G, Bianchi A and Bernardini R: Tamoxifen inhibits nerve growth factor-induced proliferation of the human breast cancerous cell line MCF-7. Cancer Res 61: 3002-3008, 2001.